Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.64 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.62 |
| ▸ | TACR1 | P25103 | 3/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736218 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL7337287 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL5916913 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL2736202 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL9421829 | 1.00 | TRPM8 (0.64) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL15241328 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL12249402 | 0.92 | TRPM8 (0.59) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL7221074 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL12249357 | 0.92 | TRPM8 (0.59) | TRPM8CTRB1TACR1CTSDCTSB | |
| SCHEMBL6925966 | 0.92 | TRPM8 (0.56) | TRPM8CTRB1TACR1CTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302468-B1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2008-12-17 | — | — | EP | disclosed |
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | KEMPF DALE J (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-1090914-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0727419-B1 | Intermediates for the preparation of retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-0732923-B1 | Pharmaceutical compositions containing HIV protease inhibitors | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150530-A | AMIDATION OF AMINE WITH ACID | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-5484801-A | Pharmaceutical composition for inhibiting HIV protease | ABBOTT LABORATORIES (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0674513-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674513-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995020384-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995009614-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1995007696-A1 | PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1993023361-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED DIAMINODIOL | ABBOTT LABORATORIES (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195362-A1 | Retroviral protease inhibiting compounds | PREP, SERPINB1, PRSS1 | TRPM8 4395/4885CTRB1 172/4885TACR1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.